Table 2. Main outcomes included in our meta-analysis.
| Author (year) | Surgical procedure | Patient number | 5-year OS rate | Total complication (%) | Recurrence (%) | Pathological up-staginga |
|---|---|---|---|---|---|---|
| Okada et al. (2006) | LND | 377 | 83.6% | 38 (10.1%) | 95(25.2%) | 2 (0.5%) |
| SND | 358 | 79.6% | 62 (17.3%) | 113 (31.6%) | 3 (0.8%) | |
| Ishiguro et al. (2010) | LND | 147 | 76.0% | NA† | NA | NA |
| SND | 625 | 71.9% | NA | NA | NA | |
| Chen et al (2012) | LND | 150 | 68.7% | 7 (4.7%) | NA | NA |
| SND | 148 | 73.6% | 20 (13.5%) | NA | NA | |
| Jiang et al (2013) | LND | 94 | 68.1% | 7 (7.4%) | 29 (30.9%) | 17 (18.0%) |
| SND | 309 | 74.4% | 14 (4.5%) | 79 (25.6%) | 59 (19.0%) | |
| Maniwa et al (2013) | LND | 129 | 89.9% | 19 (14.7%) | 24 (18.6%) | 4 (3.1%) |
| SND | 206 | 89.8% | 39 (18.9%) | 46 (22.3%) | 16 (7.8%) | |
| Ma et al (2013) | LND | 45 | 68.9% | 5 (11.1%) | NA | 5 (11.1%) |
aOnly mediastinal lymph node up-staging records were included (not N1).
LND: lobe-specific node dissection; NA: not applicable; SND: systemic lymph node dissection